SCHEMBL30643123

SCHEMBL30643123

CN(C)Cc1ccc(-n2c(C(=O)N(C)C)cc3cnc(Cl)nc32)cc1C(F)(F)F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 15/20 0.37
CCND1 P24385 6/20 0.37
CDK1 P06493 2/20 0.35
CDK2 P24941 2/20 0.35
TRPV1 Q8NER1 1/20 0.34
ATF1 P18846 1/20 0.34
NFKB1 P19838 1/20 0.34
PDE4B Q07343 1/20 0.34
PDE4D Q08499 1/20 0.34
CCNC P24863 1/20 0.33
CDK8 P49336 1/20 0.33
GAK O14976 1/20 0.33
CCNT1 O60563 1/20 0.33
CCNA2 P20248 1/20 0.33
FECH P22830 1/20 0.33
CCND3 P30281 1/20 0.33
CDK9 P50750 1/20 0.33
CDK6 Q00534 1/20 0.33
CDK16 Q00536 1/20 0.33
MAP3K1 Q13233 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26638165 1.00 CDK4 (0.37) CDK4CCND1CDK1CDK2TRPV1
SCHEMBL30643143 0.87 PDE4B (0.41) CDK4CCND1CDK1CDK2PDE4B
SCHEMBL30643112 0.87 CDK4 (0.39) CDK4CCND1CDK1CDK2PDE4B
SCHEMBL30643099 0.82 CDK4 (0.42) CDK4CCND1CDK1CDK2GAK
SCHEMBL30643135 0.82 CDK4 (0.41) CDK4CCND1CDK1CDK2GAK
SCHEMBL30643105 0.77 CDK4 (0.41) CDK4CCND1CDK2PDE4BPDE4D
SCHEMBL30643125 0.77 CDK4 (0.41) CDK4CCND1CDK1CDK2CCND3
SCHEMBL2303422 0.77 CDK4 (0.51) CDK4CCND1CDK1CDK2
SCHEMBL2304507 0.76 CDK4 (0.47) CDK4CCND1CDK1CDK2PDE4B
SCHEMBL2303125 0.74 CDK4 (0.53) CDK4CCND1CDK1CDK2TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4519267-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BeiGene, Ltd. (KY) 2025-03-12 EP disclosed
US-20250066372-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BEIGENE, LTD. (KY) 2025-02-27 US disclosed
CN-119156389-A Heterocyclic compounds, compositions thereof and methods of treatment thereof 百济神州有限公司 2024-12-17 CN disclosed
WO-2023213271-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BEIGENE , LTD. (KY) 2023-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066372-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH CDK1, CDK2, CDK4 CDK4 3/4885CCND1 69/4885CDK1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.